Nives Jonjić | Cancer Cell Biology | Women Researcher Award

Posted on by sciencefather

Prof. Dr. Nives Jonjić | Cancer Cell Biology | Women Researcher Award

Prof. Dr. Nives Jonjić | Department of Pathology and Citology, CHC Rijeka | Croatia

Prof. Nives Jonjić, MD, is a Full Professor Emeritus at the Department of General Pathology and Pathological Anatomy, Faculty of Medicine, University of Rijeka, Croatia. With a distinguished academic and clinical career spanning decades, Prof. Jonjić has made significant contributions to oncologic and molecular pathology. Her work focuses on understanding molecular markers in tumor progression and their diagnostic and prognostic relevance. As a prolific researcher and author, she has published extensively in high-impact international journals and collaborated with leading experts in pathology and oncology. Known for her diagnostic precision and dedication to academic mentorship, she has guided numerous medical students, residents, and doctoral candidates. Her legacy includes groundbreaking studies on biomarkers like Nectin-2 and Nectin-4 and rare pathologic entities. Prof. Jonjić’s leadership and scientific rigor make her a prominent figure in Croatian medical science and a respected name in international pathology circles.

Publication Profile:

Scopus

✅ Strengths for the Award:

  1. Extensive Academic and Clinical Experience
    Prof. Nives Jonjić is a Full Professor Emeritus in pathology with decades of clinical, academic, and research experience, making her a veteran in her field.

  2. Strong Research Track Record

    • Multiple first and co-authored papers in peer-reviewed journals such as Current Issues in Molecular Biology, Pathology Research and Practice, and Clinical Pathology.

    • A clear focus on oncologic pathology, including biomarkers (e.g., Nectin-2 and Nectin-4), angiogenesis, lymphomas, and myelomas.

  3. Mentorship and Academic Leadership
    She has played a key role in mentoring junior scientists, guiding doctoral research, and shaping curriculum and teaching in pathology at the University of Rijeka.

  4. Work on Rare and Challenging Diagnoses
    Her research includes diagnostic dilemmas and rare malignancies, showing depth and clinical relevance, such as CD20-negative B-cell lymphomas and extranodal Hodgkin lymphomas.

  5. Contribution to Women in Science
    As a senior female figure in medicine, her position as a full professor and mentor has made her a role model in advancing women’s participation in scientific leadership roles.

📉 Areas for Improvement:

  1. Broader International Visibility
    While her research is of high quality, greater engagement in global collaborative projects, EU-funded consortia, or as a keynote speaker in international forums could enhance her visibility outside Croatia.

  2. Higher Citation Metrics and Impact Index
    Although several of her publications are impactful, a few are recent and not yet widely cited. Participation in meta-analyses or review articles might help amplify her citation footprint.

  3. Digital and Social Research Presence
    A more proactive presence on platforms like ResearchGate, ORCID, or Google Scholar and involvement in open-access science movements could increase accessibility to her work.

🎓 Education:

Prof. Nives Jonjić completed her Medical Degree (MD) at the Faculty of Medicine, University of Rijeka, where she also pursued her postgraduate education and specialization in pathology. Her academic excellence was evident early in her medical training, leading to her progression into research and teaching. She earned her doctoral degree (PhD) with a focus on tumor biology and pathology. Over the years, she attended various advanced courses and workshops in Europe related to histopathology, immunohistochemistry, and oncologic diagnostics. Her commitment to continuous learning kept her updated with evolving trends in cancer research and molecular pathology. Through rigorous training and international collaborations, she established herself as a scholar deeply engaged with both clinical and experimental pathology. Her educational path reflects a deep integration of medical knowledge, critical inquiry, and a lifelong dedication to academic excellence.

🧪 Professional Experience:

Prof. Nives Jonjić has over 35 years of experience in academic medicine and pathology. Beginning as a junior lecturer and advancing through roles of Associate Professor and Full Professor, she served at the Faculty of Medicine, University of Rijeka, where she also led the Department of General Pathology and Pathological Anatomy. Her clinical practice included diagnostic histopathology with subspecialty interests in hematopathology, soft tissue tumors, and gynecologic oncology. She played a key role in curriculum development, faculty mentorship, and postgraduate training. As an expert pathologist, she consulted on complex diagnostic cases nationally and internationally. Beyond clinical and teaching roles, she has been a principal investigator and co-investigator in multiple research projects and has evaluated numerous PhD theses. Her rich experience spans clinical excellence, research leadership, and educational mentorship, making her a pillar in Croatian medical academia.

🏆 Awards and Honors:

Prof. Nives Jonjić has received numerous awards and accolades throughout her career for her contributions to medical research, education, and clinical pathology. Among her honors are institutional recognition for excellence in teaching from the University of Rijeka, national awards for research contributions, and commendations from Croatian medical societies. She has also been invited to deliver keynote lectures at international conferences and served as a peer reviewer for esteemed pathology journals. Her election as Full Professor Emeritus reflects the high regard in which she is held by her peers and institution. Prof. Jonjić has been actively involved in academic boards and ethical committees and received acknowledgments for advancing women’s leadership in medicine. Her work continues to inspire future generations of medical researchers and clinicians, and her accolades affirm her dedication to science, education, and healthcare.

🔬 Research Focus:

Prof. Jonjić’s research primarily focuses on tumor pathology, with special emphasis on the expression and role of molecular biomarkers such as Nectin-2, Nectin-4, osteopontin, and NF-κB in cancer progression, diagnosis, and prognosis. Her studies span various malignancies including squamous cell carcinomas, glial tumors, lymphomas, and multiple myeloma. She is also engaged in investigating rare and diagnostically challenging pathological conditions, contributing to more accurate clinical-pathologic correlations. Her recent research has emphasized angiogenesis, immune profiling, and the tumor microenvironment. She employs advanced histopathological and immunohistochemical techniques to support translational applications in pathology. Through collaboration with multidisciplinary teams, her work bridges laboratory findings with clinical decision-making. Her research is widely cited, reflecting its importance in improving diagnostic accuracy and treatment stratification in oncology. Prof. Jonjić’s academic leadership and focus on innovative diagnostic markers make her a central figure in Croatian cancer research.

📚 Publications Top Notes:

  1. 🗣️ Laryngeal Squamous Cell Carcinoma Is Characterized by a Stronger Expression of Nectin-4 Compared to Nectin-2

  2. 🧠 The Prognostic Significance of Nectin-2 and Nectin-4 Expression in Glial Tumors

  3. 💉 Anti-angiogenic Effect of Bortezomib Treatment in Multiple Myeloma Associated with Lower NF-κB and OPN Expression

  4. 🔬 Primary Nodal Unclassifiable CD20 Negative Diffuse Large B-cell Lymphoma With Dual IgK and TCR Gene Rearrangement

  5. 🦴 Angiogenesis and Osteopontin Expression in Paraskeletal Myeloma With Plasmablastic Morphology

  6. 🧪 Diagnostic Challenge of Soft Tissue Extranodal Hodgkin Lymphoma in Core-Needle Biopsy

  7. 💊 Lichen Planus Pigmentosus-like Reaction to Pirfenidone in Idiopathic Pulmonary Fibrosis

  8. 🦷 Recurrent Adamantinoma With Fibrous Dysplasia-like Feature

  9. 💉 Adalimumab as a Risk Factor for Development of Melanocytic Lesions

  10. 🧬 Expression Profiles of Metallothionein-I/II and Megalin/LRP-2 in Uterine Cervical Lesions

🏁 Conclusion:

Prof. Nives Jonjić is a highly suitable candidate for the Research for Women Researcher Award. Her scholarly contributions in pathology, especially tumor diagnostics and molecular markers, are significant and clinically relevant. Her work is anchored in academic integrity and mentorship, fostering the next generation of medical scientists. While global visibility could be enhanced, her regional impact, sustained productivity, and role as a senior academic make her a strong and deserving nominee.

 

Tamara Braut | Cancer Cell Biology | Innovative Research Award

Posted on by sciencefather

Prof. Dr. Tamara Braut | Cancer Cell Biology | Innovative Research Award

Prof. Dr. Tamara Braut | Faculty of Medicine, University of Rijeka/ENT Clinic, Clinical hospital centre Rijeka | Croatia

Professor Tamara Braut, MD, is a renowned Croatian otorhinolaryngologist and Full Professor at the Faculty of Medicine, University of Rijeka. She serves as the Head of the Department of Otorhinolaryngology and Head and Neck Surgery. Her clinical expertise and academic leadership have significantly contributed to advancements in the diagnosis and treatment of head and neck cancers, particularly laryngeal carcinoma. With over two decades of experience, Dr. Braut is widely recognized for her work in molecular oncology, HPV-associated head and neck tumors, and translational medicine. A frequent collaborator on interdisciplinary and international projects, she is committed to personalized medicine and innovative approaches in clinical research. Her impressive portfolio of peer-reviewed publications, including case studies, multicenter analyses, and biomarker-based diagnostics, highlights her dedication to evidence-based practice and academic excellence. Professor Braut’s academic leadership and clinical insight place her among the top contributors in her specialty within Croatia and internationally.

Publication Profile:

Google Scholar

Strengths For Award:

  • Pioneering work in head and neck oncology and molecular diagnostics

  • Significant publication record in high-impact journals

  • Collaborative multicenter research and precision medicine orientation

  • Demonstrated leadership in academic and clinical settings

  • Integration of clinical insights with research innovation

Areas for Improvement:

  • Broaden research beyond oncology to explore ENT-related AI/technology

  • Increase international collaborations and visibility at global conferences

  • Expand into clinical trials for therapeutics in HPV+ cancers

🎓 Education: 

Prof. Tamara Braut received her Doctor of Medicine (MD) degree from the University of Rijeka, Croatia, where she also completed her specialization in Otorhinolaryngology. Her academic path was distinguished by an early interest in oncology, molecular pathology, and surgical innovation. She pursued postgraduate training and research with a focus on laryngeal and head and neck cancers. Throughout her education, she was actively involved in academic research, participating in numerous national and international conferences, which sharpened her analytical and investigative skills. She later obtained her PhD with a focus on molecular markers in squamous cell carcinoma. Over the years, she has pursued continuous professional development in precision medicine, oncology biomarkers, and evidence-based surgical practices. Her academic and clinical training has made her a highly competent physician-scientist, well-versed in both patient care and experimental research.

🧑‍🔬 Experience:

Prof. Tamara Braut has over two decades of experience in clinical and academic medicine. She currently serves as the Head of the Department of Otorhinolaryngology and Head and Neck Surgery at the Faculty of Medicine, University of Rijeka. Her career spans clinical work, academic leadership, surgical practice, and scientific research. She has treated complex cases involving laryngeal and head-neck cancers and has led multidisciplinary teams in oncology care. As an educator, she has supervised medical students, residents, and PhD candidates, many of whom now hold academic and clinical positions. Dr. Braut is a prolific researcher, contributing to over 40 peer-reviewed articles, case studies, and reviews. Her leadership in multicenter studies and her role as a principal investigator in several clinical research projects highlight her competence in collaborative and innovative medical research.

🔬 Research Focus:

Prof. Braut’s research focus lies at the intersection of head and neck oncology, molecular diagnostics, and personalized medicine. She has a keen interest in biomarker discovery, especially in HPV-positive head and neck squamous cell carcinomas, and the role of EGFR signaling pathways in cancer progression. Her work includes translational research linking clinical findings with molecular data to improve prognosis, diagnosis, and treatment strategies. She has also explored the impact of hormonal therapies, gene expression markers like Ki-67 and IMP3, and novel imaging and diagnostic tools. In recent years, she has expanded her interest to gastroesophageal reflux disease and its implications in ENT disorders. Her contributions reflect a consistent commitment to advancing precision medicine, long-term patient follow-up, and multimodal treatment outcomes. She continues to integrate research into clinical practice, thereby fostering innovation and improved patient care in the otorhinolaryngology field.

📚 Publications List Top Notes:

  1. 🧬 Laryngeal SCC shows stronger Nectin-4 vs Nectin-2 expression – CIMB (2025)

  2. 🥗 GERD Management: From PPIs to Diet & Lifestyle – Gastrointest. Disord. (2025)

  3. 🔍 Advances in HPV-Positive Head & Neck Cancer Diagnostics – Biomolecules (2024)

  4. 🧪 Biomarkers in HPV+ Head and Neck SCC: Precision Medicine – Diagnostics (2024)

  5. 💉 Testosterone Therapy in Advanced Head & Neck SCC – Crit. Rev. Oncol. Hematol. (2023)

  6. 🏥 Long-Term Care in Laryngeal Cancer: Multicenter Analysis – J Pers. Med (2023)

  7. 📊 5-Year Clinical Course in Laryngeal Tumors – Acta Clin. Croatica (2022)

  8. 🧫 Renal Cell Carcinoma Metastasis to Larynx: Rare Case – Medicina Flum (2021)

  9. 🧠 Posttraumatic Vernet Syndrome without Fracture: Case Study – Medicine (2021)

  10. ⚛️ Nuclear EGFR Expression = Poor Survival in Laryngeal Ca – AIMM (2021)

Conclusion:

Prof. Tamara Braut is highly deserving of the Innovative Research Award. Her work showcases originality, clinical relevance, and scientific depth. With a robust academic and clinical foundation, she continues to push the boundaries in ENT oncology and diagnostics.

 

Dalia Saleh | Cancer Cell Biology | Innovative Research Award

Posted on by sciencefather

Prof. Dalia Saleh | Cancer Cell Biology | Innovative Research Award

Prof. Dalia Saleh, National Research Centre, Egypt

Dr. Dalia Osama Abd El Fattah Saleh is a distinguished pharmacologist and professor at the National Research Centre, Cairo, Egypt. With a career spanning over two decades in academic and pharmaceutical research, she specializes in molecular pharmacology, experimental therapeutics, and drug development. She earned her Ph.D. and M.Sc. in Pharmacology from Cairo University, where she also completed her undergraduate pharmacy degree with honors. Dr. Saleh’s prolific contributions to science are reflected in her extensive publication record, focusing on novel therapeutic strategies against various toxicological, metabolic, and inflammatory disorders. Her collaborative efforts have led to advancements in drug signaling pathways, phytochemical pharmacology, and nanotechnology-based delivery systems. Recognized nationally for her innovation, she has received several prestigious awards. Dr. Saleh continues to shape pharmacological research through her dedication to translational science, mentorship, and participation in international seminars and training programs.

Publication Profile: 

Google Scholar

✅ Strengths for the Award:

  • Extensive Academic Background: Holds a Ph.D., M.Sc., and B.Sc. in Pharmacology from Cairo University, with a clear focus on endocrine and vascular pharmacology from early in her career.

  • Distinguished Research Record: Authored over 25+ high-impact publications in peer-reviewed journals including Scientific Reports, Toxicology Reports, Biochemistry and Cell Biology, and Environmental Science and Pollution Research.

  • Novel Scientific Contributions:

    • Explores molecular pharmacology through cutting-edge therapeutic approaches like AMPK/mTOR signaling, Nrf2/NF-κB modulation, and natural compound pharmacodynamics.

    • Studies involve both synthetic and phytochemical-based interventions, representing a hybrid and innovative research style.

  • Awards and Recognition:

    • National recognition for her research quality and productivity by the National Research Centre, with awards received in 2015 and 2020.

    • Ranked 24th in the institution for publication volume in 2014—an indicator of sustained output.

  • Global Exposure: Participated in professional training programs at King’s College London, enhancing her knowledge in clinical drug development and data management—an asset for interdisciplinary and translational research.

  • Leadership and Longevity: Promoted through all academic ranks at NRC, from Research Assistant to Professor, demonstrating not only competence but leadership and mentorship over time.

Areas for Improvement:

  • Clinical Translation: While the preclinical research is extensive, initiating clinical trials or translational studies would further strengthen the real-world applicability of her findings.

  • Global Visibility: Although trained internationally, more international speaking engagements, keynote invitations, or editorial roles could enhance global recognition.

  • Interdisciplinary Projects: Expanding collaborations across fields such as bioinformatics or biotechnology could amplify the innovation aspect of her work.

🎓 Education:

Dr. Dalia Saleh obtained all her academic degrees from Cairo University’s esteemed Faculty of Pharmacy. She was awarded her Ph.D. in Pharmacology in 2012 for her thesis examining estrogen’s vascular effects in insulin-resistant, ovariectomized rats. Earlier, she earned her M.Sc. in 2009 with research on rosiglitazone’s effects in streptozotocin-induced vascular changes. Her academic journey began with a B.Sc. in Pharmacy in 2002, graduating with distinction and honors. Her strong educational foundation laid the groundwork for her innovative and interdisciplinary research spanning molecular pharmacology, toxicology, and metabolic disorders. Through continuous professional development, including modules at King’s College London, Dr. Saleh stays aligned with global standards in pharmacological science and clinical drug development. Her educational background combines academic excellence with practical research expertise, making her well-equipped to address complex biomedical challenges.

👩‍🔬 Experience:

Dr. Dalia Saleh has built a progressive research career at Egypt’s National Research Centre, beginning as a Research Assistant in 2003. Over the years, she rose through the ranks to become a Professor in 2022. She previously held positions as Researcher (2012–2017) and Assistant Professor (2017–2022). Throughout her tenure, she has actively contributed to preclinical pharmacology research, focusing on inflammation, neuroprotection, metabolic diseases, and organ toxicity. Her interdisciplinary approach integrates pharmacodynamics, molecular signaling, and therapeutic intervention studies using both synthetic and natural compounds. She has led numerous studies that explore drug mechanisms at cellular and systemic levels, often employing rodent disease models. Dr. Saleh’s active participation in international training (e.g., at King’s College London) highlights her global engagement and commitment to continuous learning. Her career reflects not only research productivity but also leadership in collaborative scientific initiatives and mentoring of emerging researchers.

🏆 Awards & Honors:

Dr. Dalia Saleh has received multiple accolades that underscore her impact in the field of pharmacology. She was honored with the 2020 Scientific Pioneers Award and the 2015 Scientific Encouragement Award from Egypt’s National Research Centre (NRC), recognizing her outstanding research contributions. In 2014, she received institutional recognition for both her high publication output (ranked 24th NRC-wide) and for publishing in a high-impact journal (impact factor 4.067). These achievements highlight her consistent scientific productivity and influence in biomedical research. Dr. Saleh’s awards reflect a career driven by innovation, rigor, and dedication to solving pressing health issues. Her work continues to be widely cited and applied in translational pharmacology, securing her reputation as a leading figure in her discipline. She remains an inspiration to peers and students alike, with a legacy of both scientific excellence and mentorship.

🔬 Research Focus:

Dr. Dalia Saleh’s research is rooted in experimental pharmacology, with an emphasis on cell signaling pathways, drug discovery, and natural compound pharmacodynamics. She investigates molecular mechanisms underlying chronic diseases such as diabetes, hepatic and renal injury, neurodegeneration, and inflammatory disorders. A recurring theme in her work is the modulation of key signaling axes (e.g., AMPK/mTOR, NF-κB, PI3K/Akt) in mitigating organ toxicity and disease progression. Her recent studies explore the pharmacological potential of phytochemicals, drug hybrids, and nanoformulations in preclinical models. Dr. Saleh also examines gender-specific pathophysiology, as seen in her Ph.D. research on estrogen’s role in vascular dysfunction. She actively integrates biochemical, histological, and behavioral endpoints to ensure translational relevance. By bridging traditional medicine and molecular pharmacology, her work contributes to next-generation therapeutics and precision medicine. Her research has both national and global impact, frequently published in high-tier journals and cited in clinical research discussions.

📚 Publications Top Notes:

  1. 🧬 Eugenol alleviates acrylamide-induced testicular toxicity via AMPK/pAKT/mTOR signaling – Scientific Reports, 2024

  2. 💊 Trimetazidine protects against cisplatin-induced neuropathy via AMPK and Nrf2 pathways – Biochemistry and Cell Biology, 2023

  3. 🧪 Chromone-thiazolopyrimidine hybrids inhibit TNF-α, IL-6, and PGE2 – Polycyclic Aromatic Compounds, 2023

  4. 🧻 Chrysin counters cyclophosphamide-induced cystitis via STAT-3 and NF-κB inhibition – Chemico-Biological Interactions, 2023

  5. 🩺 Linagliptin and L-arginine synergize in hyperacidity via EP4 upregulation – Naunyn-Schmiedeberg’s Archives of Pharmacology, 2023

  6. 🧠 L-arginine protects against hepatic encephalopathy via anti-apoptotic mechanisms – Environmental Science and Pollution Research, 2023

  7. 🌿 Calotropis procera seed oil shows anti-inflammatory and antiparasitic activity – Arabian Journal of Chemistry, 2022

  8. 🧫 Olmesartan mitigates diabetic nephropathy through TLR4/P38-MAPK modulation – European Journal of Pharmacology, 2022

  9. 🌱 Anti-fibrotic activities of Plumbago species in liver fibrosis models – Scientific Reports, 2022

  10. 🐟 Omega-3 fatty acids protect against doxorubicin-induced liver damage – Saudi Journal of Biological Sciences, 2022

Conclusion:

Dr. Dalia O. Saleh is highly suitable for the Best Researcher Award based on her prolific scientific contributions, consistent academic progression, and commitment to impactful pharmacological research. Her strength lies in combining rigorous mechanistic studies with applied therapeutic exploration, especially in inflammation, oxidative stress, and natural product pharmacology.

Wei Xue | Cancer Cell Biology | Best Academic Researcher Award

Posted on by sciencefather

Mr. Wei Xue | Cancer Cell Biology | Best Academic Researcher Award

Mr. Wei Xue , Renji Hospital, School of Medicine, Shanghai Jiaotong University , China

Dr. Xue Wei, M.D., Ph.D., is a distinguished urologist, professor, and researcher specializing in genitourinary oncology. Currently serving as the Vice President of Renji Hospital, Shanghai Jiao Tong University School of Medicine, he also leads its Department of Urology. With over 150 publications, including 100+ SCI-indexed papers, Dr. Xue is a leading expert in minimally invasive urological surgeries, particularly robotic-assisted procedures. He has made significant contributions to prostate cancer treatment and multidisciplinary approaches for metastatic prostate cancer. Dr. Xue is an executive member of various prestigious medical organizations, including the Chinese Medical Association and the European Association of Urology. His groundbreaking research and clinical excellence have earned him multiple accolades, including “Shanghai Leading Talent” and “Outstanding Academic Leader.” With a strong dedication to advancing medical technology and patient care, Dr. Xue continues to shape the future of urological oncology through his pioneering work in surgery, research, and mentorship.

Publication Profile:

Scopus

Strengths for the Award:

  1. Extensive Research Contributions 📚 – Dr. Xue Wei has over 150 publications, including 100+ SCI-indexed papers, highlighting his impactful work in genitourinary oncology.

  2. Leadership & Influence 🌍 – As Vice President of Renji Hospital and Director of Urology, he plays a crucial role in shaping the future of urological research and treatment.

  3. Clinical Expertise 🏥 – He is an expert in robot-assisted and minimally invasive surgeries, particularly nerve-sparing radical prostatectomy and multidisciplinary management of metastatic prostate cancer.

  4. High-Impact Research Grants 💰 – Principal investigator for 12 key research projects, including those funded by the National Natural Science Foundation of China.

  5. Prestigious Recognitions 🏆 – Titles like Shanghai Leading Talent and Outstanding Academic Leader reflect his excellence in academia and clinical practice.

📌 Areas for Improvement:

  1. Citations & Impact Factor Growth – While his publication count is high, increasing citations and impact factor of his papers would further establish global recognition.

  2. Global Collaboration – Expanding international partnerships and multicenter clinical trials could enhance his research influence beyond China.

  3. Innovative Breakthroughs – While excelling in robotic-assisted surgery, pioneering novel therapeutic strategies could further elevate his status as a global thought leader.

🎓 Education:

Dr. Xue Wei completed his M.D. and Ph.D. in Urology at Shanghai Jiao Tong University School of Medicine, a premier institution in China known for its rigorous medical training and research excellence. He further honed his expertise through international academic collaborations, including a tenure as a Visiting Associate Professor at the MD Anderson Cancer Center, USA. His academic journey was marked by intensive research in genitourinary oncology, robotic-assisted surgeries, and advanced treatment modalities for prostate and renal cancers. Over the years, he has received advanced training in minimally invasive urological surgery, leveraging cutting-edge technology to improve surgical outcomes. His strong academic foundation, combined with a commitment to innovation, has made him a globally recognized expert in urological oncology. Through continuous education and research leadership, Dr. Xue remains at the forefront of medical advancements, ensuring his contributions have a lasting impact on both clinical practice and scientific research.

💼 Experience:

Dr. Xue Wei boasts a distinguished career spanning decades in clinical practice, research, and academic leadership. He is the Vice President of Renji Hospital, Shanghai Jiao Tong University School of Medicine, and Director of its Department of Urology. As a key figure in the Chinese and international urology communities, he holds executive positions in prestigious organizations such as the Chinese Medical Association, European Association of Urology, and American Urological Association. Dr. Xue specializes in minimally invasive and robotic-assisted urological surgeries, pioneering advanced techniques in radical prostatectomy and cancer treatment. His leadership extends to mentoring doctoral students and overseeing high-impact research projects funded by national and municipal grants. His role as a principal investigator in groundbreaking studies has led to over 150 peer-reviewed publications. With his clinical expertise, surgical innovations, and research contributions, Dr. Xue remains a leader in shaping the future of urological oncology.

🏆 Awards & Honors:

Dr. Xue Wei has earned numerous prestigious accolades in recognition of his contributions to urological research and clinical excellence. Among his most notable honors are:

  • Shanghai Leading Talent 🌟

  • Outstanding Academic Leader, Shanghai 🏅

  • Shanghai Medical Leading Talent 🎖️

  • Shanghai Craftsman & Shanghai Medical Craftsman 🏆

As a globally recognized expert, Dr. Xue’s pioneering work in robotic-assisted surgery and genitourinary oncology has solidified his reputation as a leading academician and clinician. His dedication to advancing minimally invasive surgery and cancer treatment has not only influenced medical practice in China but also gained international recognition. He serves as a mentor and research leader, shaping the next generation of urologists. With his exceptional achievements, Dr. Xue continues to set benchmarks in urological science, making him a strong contender for the Best Academic Researcher Award.

🔬 Research Focus:

Dr. Xue Wei’s research primarily focuses on genitourinary oncology, with a particular emphasis on prostate cancer, kidney cancer, and minimally invasive surgery. He has led multiple high-impact studies on robot-assisted laparoscopic procedures, multidisciplinary management of metastatic prostate cancer, and biomolecular mechanisms of cancer progression. His work in precision medicine and targeted therapies has contributed to advancements in prostate cancer treatment, enhancing survival outcomes and treatment efficacy.

As the principal investigator of 12 research projects funded by the National Natural Science Foundation of China and the Shanghai Municipal Education Commission, Dr. Xue has pushed the boundaries of medical innovation. His recent research explores the role of m6A RNA modifications, immunotherapy, and cancer stem cells in drug resistance and tumor aggressiveness. His contributions have transformed clinical practices, bridging the gap between cutting-edge research and real-world patient care, making him a global leader in urological oncology research.

📚 Publications Top Notes:

  1. AGD1/USP10/METTL13 Complexes Enhance Cancer Stem Cells Proliferation and Diminish the Therapeutic Effect of Docetaxel 🔬🧬

  2. Specific Activation of cGAS-STING Pathway by Manganese-Doped Bioactive Glasses for Boosting Systemic Tumor Immunotherapy 🏥🧪

  3. Osalmid Sensitizes Clear Cell Renal Cell Carcinoma to Navitoclax Through a STAT3/BCL-XL Pathway 🏥💊

  4. Efficacy and Predictive Factors Analysis of Androgen Deprivation Plus Novel Hormone Therapy as Neoadjuvant Treatment for High-Risk Prostate Cancer 🔎⚕️

  5. Open Nephron-Sparing Surgery Strategy for Renal Angiomyolipoma with Vena Cava Thrombus 🏥🔬

  6. A Phase II Study of Tislelizumab as Neoadjuvant Treatment for Cisplatin-Ineligible High-Risk Upper Tract Urothelial Carcinoma 💉🔬

  7. Proportion of Gleason Score ≥8 Prostate Cancer on Biopsy and Tumor Aggressiveness in East Asian vs. Non-East Asian Men 🧬🧑‍⚕️

  8. Iron-Loaded Cancer-Associated Fibroblasts Induce Immunosuppression in Prostate Cancer 🩸🛡️

  9. A Multi-Classifier System Integrated by Clinico-Histology-Genomic Analysis for Predicting Recurrence of Papillary Renal Cell Carcinoma 🏥📊

🏅 Conclusion:

Dr. Xue Wei is a highly suitable candidate for the Best Academic Researcher Award due to his exceptional contributions in urological oncology, leadership in clinical research, and dedication to innovation. His extensive academic output, surgical expertise, and impact on medical education make him a leading figure in his field. Enhancing global collaborations and high-impact publications would further solidify his legacy as a world-class researcher. 🚀